Feature | January 30, 2015

ECRI Institute Offers Overview on Drug-eluting Balloons

While shown to offer better outcomes for peripheral artery disease, higher cost slowing adoption in the United States

drug-eluting balloons, DEB, ECRI, report, peripheral artery disease, PAD, cath
The Bard Lutonix drug-eluting balloon was cleared by the FDA last November.

January 30, 2015 — ECRI Institute has created a report that offers an overview of drug-eluting balloon (DEB) technology, “Health Technology Forecast report, "Drug-eluting Angioplasty Balloons for Preventing Restenosis after Revascularization." The report details some of the key questions regarding DEBs.

Balloon angioplasty to treat peripheral artery disease is associated with high rates of restenosis, or re-narrowing of the arteries. For certain indications, such as long lesions in below-the-knee arteries, the one-year restenosis rate following peripheral angioplasty may be as high as 70 percent. To address this problem, several manufacturers have been developing drug-eluting balloons as an alternative to conventional angioplasty balloons for performing percutaneous transluminal angioplasty, and the first one recently received U.S. Food and Drug Administration (FDA) approval.

Excerpts of the ECRI report are below:

What Do Drug-eluting Balloons Do?

Drug-eluting balloons are designed to deliver their drug dose over several minutes. Most peripheral artery drug-eluting balloons in clinical use or in development are coated with paclitaxel, an antiproliferative drug commonly used in older drug-eluting stents designed for the coronary arteries. The drug inhibits cell proliferation for an extended time and therefore may significantly reduce scar tissue formation in blood vessels. Most current-generation coronary drug-eluting stents are coated with everolimus or zotarolimus. Other antiproliferative agents are also under investigation for use with peripheral drug-eluting balloons.

 

Widespread Use Depends on Reimbursement

Drug-eluting balloons have been proposed to replace conventional uncoated angioplasty balloons to reduce restenosis rates in treating peripheral artery disease, with or without implantation of a bare-metal stent or drug-eluting stent. ECRI Institute's expert panel commenting on this technology thought that the substantially higher cost of drug-eluting balloons compared with uncoated balloons could limit broader use of the technology unless additional reimbursement becomes available from third-party payers.

 

Better Outcomes with Drug-eluting Balloons

The expert panel thought that data thus far suggest that drug-eluting balloons may provide better outcomes than uncoated angioplasty balloons in the peripheral arteries. Their use might also reduce the need for repeat intervention to treat re-narrowed arteries and might lessen the anticlotting drug therapy needed after conventional angioplasty for peripheral artery disease. The panel noted that data have not yet shown any definitive effect from this technology on patient outcomes of reduced limb amputation or longer survival.

 

The Device is Expected to Inflate Hospital Budgets
The panel noted that the anticipated cost of drug-eluting balloons in the United States is up to five times more than conventional angioplasty balloons for peripheral artery disease, but comparable to peripheral drug-eluting stents. Additional reimbursement for drug-eluting balloons (i.e., above the rate reimbursed for uncoated balloon angioplasty) is not available from public and private third-party payers at this time. The panel thought the financial impact could be greater for indications in which permanent stent implantation is less common such as below-the-knee peripheral artery disease. Data suggest that drug-eluting balloons might reduce the need for repeat interventions and lower overall treatment costs compared with conventional peripheral angioplasty, despite the higher initial device costs. If drug-eluting balloons are shown to have comparable long-term efficacy to peripheral drug-eluting stents for reducing restenosis, their use might somewhat reduce costs of treating peripheral artery disease. However, improved outcomes could also reduce hospital revenue if patients need fewer interventions and less care.   

For more information: www.ecri.org

Related Content

News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Technology | Balloon Catheter

August 23, 2018 — W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance ...

Home August 23, 2018
Home
Technology | Balloon Catheter

March 21, 2018 — Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) ...

Home March 21, 2018
Home
News | Balloon Catheter

January 24, 2018 — Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product ...

Home January 24, 2018
Home
News | Balloon Catheter

May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports of ...

Home May 22, 2017
Home
Subscribe Now